Sunvozertinib (DZD9008) shows superior efficacy in NSCLC patients harboring EGFR exon 20 insertion mutations after platinum and anti-PD(L)1 treatment failures
Golidocitinib (DZD4205) demonstrates enormous potential for peripheral T-cell lymphoma
DZD1516 exemplifies full BBB-penetration in patients with HER2 positive metastatic breast cancer
Further data will highlight the clinical pharmacokinetic/pharmacodynamic relationship of DZD2269, a potent and selective A2aR antagonist designed to overcome high levels of adenosine induced immunosuppression
SHANGHAI, May 27, 2022 /PRNewswire/ -- Dizal will present clinical results and updates from its four therapeutic candidates in solid tumors and hematologic malignancies at the 2022 Annual Meeting of the American Society of Cancer Oncology (ASCO) being held on June 3-7, 2022. New data from Dizal's investigational cancer medicines demonstrate the rapid progression of its oncology pipeline.
Clinical portfolio to be presented include:
"We are thrilled to have such a robust presence at this year's ASCO. These data presentations reflect the quality of our science and our important work to deliver innovative therapies for hard-to-treat diseases." said Dr. Xiaolin Zhang, CEO of Dizal, "Building on our extensive expertise in translational science and blood brain barrier research, we have established an internationally competitive portfolio of five clinical-stage assets with two leading assets at global pivotal studies."
Dizal's Presentations at ASCO 2022
Lead Author |
Abstract Title |
Presentation details |
Prof. Pasi A. Janne |
Antitumor activity of |
Abstract #9015 Poster Discussion Session Lung Cancer—Non-Small Cell Session Date and Time: June 6, Poster Session Lung Cancer—Non-Small Cell Session Date and Time: June 6, |
Prof. Won Seog |
A phase I/II study of |
Abstract #7563 Poster Session Hematologic Malignancies – Session Date and Time: June 4, |
Prof. Xichun Hu |
Early clinical safety and |
Abstract #1038 Poster Session Breast Cancer—Metastatic | Hall A Session Date and Time: Monday, June 6, 2022, 08:00 CDT |
Ziyi Liu PhD |
Clinical pharmacokinetic / |
Abstract #e15106 Online publication |
About Dizal
Dizal Pharmaceutical is a clinical stage, biopharmaceutical company. At Dizal we aspire to discover and develop differentiated therapeutics for the treatment of cancer and immunological diseases. Building on our extensive expertise in translational science and molecular design, we have established an internationally competitive portfolio with two leading assets at global pivotal studies.
Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Dizal, are intended to identify certain of such forward-looking statements. Dizal does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Dizal's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal's competitive environment and political, economic, legal and social conditions.
Dizal, the Directors and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.
Contacts
Investor Relations: ir@dizalpharma.com
Business Development: bd@dizalpharma.com
View original content:https://www.prnewswire.com/news-releases/dizal-to-demonstrate-the-strength-and-rapid-acceleration-of-its-clinical-portfolio-at-asco-2022-301556470.html